MA45087A - 3-oxo-2,6-diphényl-2,3-dihydropyridazine-4-carboxamides - Google Patents

3-oxo-2,6-diphényl-2,3-dihydropyridazine-4-carboxamides

Info

Publication number
MA45087A
MA45087A MA045087A MA45087A MA45087A MA 45087 A MA45087 A MA 45087A MA 045087 A MA045087 A MA 045087A MA 45087 A MA45087 A MA 45087A MA 45087 A MA45087 A MA 45087A
Authority
MA
Morocco
Prior art keywords
dihydropyridazine
carboxamides
diphenyl
oxo
Prior art date
Application number
MA045087A
Other languages
English (en)
Inventor
Benjamin Bader
Ilona Gutcher
Horst Irlbacher
Michael Platten
Ulrike Roehn
Lars Roese
Norbert Schmees
Detlef Stoeckigt
Na Zhao
Ludwig Zorn
Original Assignee
Bayer Pharma AG
Deutsches Krebsforschungszentrum Dkfz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Deutsches Krebsforschungszentrum Dkfz filed Critical Bayer Pharma AG
Publication of MA45087A publication Critical patent/MA45087A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14Oxygen atoms
    • C07D237/16Two oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA045087A 2016-05-25 2017-05-23 3-oxo-2,6-diphényl-2,3-dihydropyridazine-4-carboxamides MA45087A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2016083308 2016-05-25
CN2017074408 2017-02-22

Publications (1)

Publication Number Publication Date
MA45087A true MA45087A (fr) 2021-05-26

Family

ID=58745251

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045087A MA45087A (fr) 2016-05-25 2017-05-23 3-oxo-2,6-diphényl-2,3-dihydropyridazine-4-carboxamides

Country Status (28)

Country Link
US (1) US11040035B2 (fr)
EP (1) EP3464248B1 (fr)
JP (1) JP6964096B2 (fr)
KR (1) KR20190009369A (fr)
CN (1) CN109863140B (fr)
AU (1) AU2017269870A1 (fr)
BR (1) BR112018074185A2 (fr)
CA (1) CA3025227A1 (fr)
CL (1) CL2018003345A1 (fr)
CO (1) CO2018012654A2 (fr)
CR (1) CR20180556A (fr)
CU (1) CU20180143A7 (fr)
DO (1) DOP2018000256A (fr)
EA (1) EA201892666A1 (fr)
EC (1) ECSP18087725A (fr)
IL (1) IL263046A (fr)
JO (1) JOP20170126A1 (fr)
MA (1) MA45087A (fr)
MX (1) MX2018014443A (fr)
NI (1) NI201800124A (fr)
PE (1) PE20190509A1 (fr)
PH (1) PH12018502472A1 (fr)
SG (1) SG11201810366WA (fr)
SV (1) SV2018005787A (fr)
TN (1) TN2018000392A1 (fr)
TW (1) TW201742859A (fr)
UY (1) UY37256A (fr)
WO (1) WO2017202816A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI759301B (zh) 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
JOP20190193A1 (ar) * 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
WO2019101647A1 (fr) * 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 2-phénylpyrimidine-4-carboxamides à utiliser en tant qu'inhibiteurs d'ahr
PT3580211T (pt) * 2017-11-21 2021-02-01 Deutsches Krebsforsch 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro
CA3082857A1 (fr) * 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
EP3713922A1 (fr) 2017-11-21 2020-09-30 Bayer Aktiengesellschaft 3-oxo-2,3-dihydropyridazine-4-carboxamides substitués par du soufre
US12221439B2 (en) 2018-08-24 2025-02-11 Jaguahr Therapeutics Pte Ltd Tetrahydropyridopyrimidine derivatives as AhR modulators
KR20210053911A (ko) 2018-08-31 2021-05-12 재규어 테라퓨틱스 피티이 리미티드 Ahr 조절제로서의 헤테로사이클릭 화합물
CN109771437B (zh) * 2019-03-28 2023-03-17 西安交通大学医学院第一附属医院 三氟胸苷在制备治疗三阴性乳腺癌药物中的应用
EP3715471A1 (fr) * 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ensemble de marqueur de signature d'ahr
EP3721894A1 (fr) 2019-04-10 2020-10-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Gène 1 induit par l'interleukine-4 (il4i1) en tant que biomarqueur et ses utilisations
EP4005637A4 (fr) * 2019-07-29 2023-07-19 Takeda Pharmaceutical Company Limited Composé hétérocyclique
EP3835432A1 (fr) 2019-12-10 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Gène 1 induit par l'interleukine-4 (il4i1) et métabolites respectifs en tant que biomarqueurs pour le cancer
US20230084899A1 (en) * 2019-12-16 2023-03-16 Bayer Aktiengesellschaft Combination of an ahr-inhibitor and an pd1-inhibitor antibody and its use in the treatment of cancer
AU2021206696A1 (en) 2020-01-10 2022-08-04 Ikena Oncology, Inc. AHR inhibitors and uses thereof
WO2021173082A1 (fr) 2020-02-26 2021-09-02 Jaguahr Therapeutics Pte Ltd Dérivés de pyridopyrimidine utiles dans la modulation de la signalisation de l'ahr
JP7651590B2 (ja) * 2020-03-27 2025-03-26 ドン-ア エスティ カンパニー リミテッド アミノピリミジン誘導体およびアリール炭化水素受容体モジュレーターとしてのその使用
US11911376B2 (en) 2020-03-30 2024-02-27 The Regents Of The University Of Colorado Methods for preventing and treating retinal damage
US12570638B2 (en) 2020-05-20 2026-03-10 Sail Biomedicines, Inc. Fused imidazole derivatives as AHR antagonists
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
WO2022078356A1 (fr) * 2020-10-15 2022-04-21 山东轩竹医药科技有限公司 Inhibiteur d'ahr hétéroaromatique
CN114685426A (zh) * 2020-12-28 2022-07-01 苏州泽璟生物制药股份有限公司 磺酰胺类抑制剂及其制备方法和应用
EP4402130A1 (fr) * 2021-09-14 2024-07-24 Allianthera (Suzhou) Biopharmaceutical Co., Ltd. Modulateurs des récepteurs d'hydrocarbures 2-aryle ou hétéroaryl-3-oxo-4-carbamide-6-cyclique-dihydropyrazine aryle et leur utilisation dans le traitement de maladies et d'affections
CN119948035A (zh) 2022-10-03 2025-05-06 捷豹治疗有限公司 可用于调节AhR信号传导的化合物
WO2025114771A1 (fr) 2023-11-29 2025-06-05 Latvian Institute Of Organic Synthesis Nouvelle classe d'antagonistes du récepteur aryl hydrocarbone et leur optimisation
WO2026027421A1 (fr) 2024-07-30 2026-02-05 Leibniz-Institut Für Pflanzenbiochemie Dérivés de 4-oxo-1,4-dihydropyridazine utilisés en tant qu'agonistes du récepteur d'hydrocarbure aryle pour le traitement du cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134467A1 (de) 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU756275B2 (en) * 1998-08-14 2003-01-09 Nihon Nohyaku Co., Ltd. Pyridazinone derivatives
CA2742411A1 (fr) * 2000-09-18 2002-03-21 Eisai R&D Management Co., Ltd. Composes de pyridazinone et triazinone et leur utilisation comme preparations pharmaceutiques
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
FR2847235B1 (fr) 2002-11-20 2005-07-08 Essilor Int Emballage de protection et de calage pour objets a contour circulaire
WO2007058392A1 (fr) 2005-11-21 2007-05-24 Japan Tobacco Inc. Composé hétérocyclique et son application médicale
EP2328586A2 (fr) 2008-05-20 2011-06-08 Cephalon, Inc. Dérivés pyridazinone substitués comme ligands des récepteurs de l'histamine-3 (h3)
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CA2807199C (fr) 2010-07-27 2020-07-07 Northeastern University Modulateurs du recepteur d'aryl d'hydrocarbone derive de flavonoide utiles dans le traitement du cancer
WO2015143164A1 (fr) * 2014-03-19 2015-09-24 President And Fellows Of Harvard College Agents antimicrobiens et procédés de criblage
JOP20190193A1 (ar) * 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان

Also Published As

Publication number Publication date
AU2017269870A1 (en) 2018-12-06
DOP2018000256A (es) 2019-02-15
EP3464248B1 (fr) 2021-09-08
JP2019516744A (ja) 2019-06-20
CN109863140B (zh) 2023-02-21
UY37256A (es) 2018-01-02
WO2017202816A1 (fr) 2017-11-30
PE20190509A1 (es) 2019-04-10
JOP20170126A1 (ar) 2017-11-25
CL2018003345A1 (es) 2019-03-15
CR20180556A (es) 2019-04-23
MX2018014443A (es) 2019-04-15
PH12018502472A1 (en) 2019-09-23
IL263046A (en) 2018-12-31
US20200237757A1 (en) 2020-07-30
JP6964096B2 (ja) 2021-11-10
EP3464248A1 (fr) 2019-04-10
CU20180143A7 (es) 2019-07-04
TW201742859A (zh) 2017-12-16
KR20190009369A (ko) 2019-01-28
CO2018012654A2 (es) 2018-12-14
EA201892666A1 (ru) 2019-08-30
TN2018000392A1 (en) 2020-06-15
US11040035B2 (en) 2021-06-22
BR112018074185A2 (pt) 2019-03-06
ECSP18087725A (es) 2018-11-30
SV2018005787A (es) 2019-02-07
SG11201810366WA (en) 2018-12-28
CA3025227A1 (fr) 2017-11-30
NI201800124A (es) 2019-04-29
CN109863140A (zh) 2019-06-07

Similar Documents

Publication Publication Date Title
MA45087A (fr) 3-oxo-2,6-diphényl-2,3-dihydropyridazine-4-carboxamides
DK3405050T3 (da) Børnesikret snusbeholder
LT3230281T (lt) 1,3-tiazol-2-ilu pakeisti benzamidai
DK3436823T3 (da) Antigen-array
EP3713931C0 (fr) 3-oxo-6-hétéroaryl-2-phényl-2,3-dihydropyridazine-4-carboxamides
DK3335532T3 (da) Tandharve
DK3402792T3 (da) Quinolin-2-on-derivater
DK3445708T3 (da) Stigbøjle
FR3023988B3 (fr) .
DK3452590T3 (da) Plademagnet
DK3509963T3 (da) Pallecontainer
DK3528829T3 (da) Bacitracin-alginat-oligomer-konjugater
IT201600084952A1 (it) Coglifrutta.
DK3575238T3 (da) Pallecontainer
EP3619920A4 (fr) Interactions d'objets audio sans métadonnées
ES1150114Y (es) Abarcón.
EP3486310A4 (fr) Souche deleuconostoc mesenteroides
EP3399976C0 (fr) Amphophiles de benzothiazole
DE112017000734A5 (de) Glycolsensor
DE112017006386A5 (de) Schraubarbeitszylinder
DK3323708T3 (da) Bovfender
DK3452587T3 (da) Penicillin-g-acylaser
DK3430609T3 (da) Smartflag
EP3400237A4 (fr) Analogues peptidiques
DK3471535T3 (da) Dyrelift